{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:59:01Z","timestamp":1781647141372,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The optimal prognostication model for outcome following allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) remains undefined. To establish a prognostic scoring system, 466 consecutive AML patients undergoing allo-HSCT from 2014 to 2023 were analyzed as a training cohort. Six donor, leukemia and recipient related factors were identified as prognostically significant and assigned weighted scores, respectively 1 point each for donor cytomegalovirus seropositivity, Hemopoietic Cell Transplantation-specific Comorbidity Index\u2009\u2265\u20092, secondary AML, not in first complete remission, and low-intensity induction therapy; 3 points for inv(3)\/t(3;3)(q21;q26) or\n                    <jats:italic>KMT2A<\/jats:italic>\n                    rearrangement; 4 points for \u2212\u20095\/del(5q) or\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation; 0 point for\n                    <jats:italic>CEBPA<\/jats:italic>\n                    bZIP in-frame mutation or core-binding factor AML; and 1 point for all other genetic risk groups. Scores were grouped into four risk categories: favorable (0\u20131), intermediate (2\u20133), poor (4\u20135), and very poor (\u2265\u20096); constituting the HATS prognostication model. The corresponding 2-year overall survivals of favorable, intermediate, poor and very poor risk groups were 92%, 78%, 50%, and 7.4% (log-rank\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). An external validation cohort comprising 395 patients was similarly analyzed. With concordance statistics, HATS outperformed all six existing prognostication models. In conclusion, HATS represents a novel prognostication model devised for AML patients undergoing allo-HSCT.\n                  <\/jats:p>\n                  <jats:p>Clinicaltrials.gov identifier: NCT06702111.<\/jats:p>","DOI":"10.1007\/s00277-026-06989-z","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:36:30Z","timestamp":1775712990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel prognostic scoring system HATS for acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"105","author":[{"given":"Garret M K","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelyn P.Y.","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"12","key":"6989_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute Myeloid Leukemia. N Engl J Med 373(12):1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"issue":"23","key":"6989_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O\u2019Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Dohner K, Schlenk RF, Dohner H, Campbell PJ (2016) Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374(23):2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"6989_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/asheducation-2014.1.495","volume":"2014 1","author":"S Bhatia","year":"2014","unstructured":"Bhatia S (2014) Caring for the long-term survivor after allogeneic stem cell transplantation. Hematol Am Soc Hematol Educ Program 2014 1:495\u2013503. https:\/\/doi.org\/10.1182\/asheducation-2014.1.495","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"24","key":"6989_CR4","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, Duarte RF, Kroger N, Schoemans H, Koenecke C, Peric Z, Basak GW (2020) How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv 4(24):6283\u20136290. https:\/\/doi.org\/10.1182\/bloodadvances.2020003418","journal-title":"Blood Adv"},{"issue":"8","key":"6989_CR5","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"6","key":"6989_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/bmt.2011.110","volume":"47","author":"A Gratwohl","year":"2012","unstructured":"Gratwohl A (2012) The EBMT risk score. Bone Marrow Transpl 47(6):749\u2013756. https:\/\/doi.org\/10.1038\/bmt.2011.110","journal-title":"Bone Marrow Transpl"},{"issue":"23","key":"6989_CR7","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W (2014) Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123(23):3664\u20133671. https:\/\/doi.org\/10.1182\/blood-2014-01-552984","journal-title":"Blood"},{"issue":"1","key":"6989_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/leu.2014.164","volume":"29","author":"J Versluis","year":"2015","unstructured":"Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, Nagler A, Blaise D, Rocha V, Cornelissen JJ, Mohty M (2015) Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia 29(1):51\u201357. https:\/\/doi.org\/10.1038\/leu.2014.164","journal-title":"Leukemia"},{"issue":"28","key":"6989_CR9","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2014.59.1339","volume":"33","author":"R Shouval","year":"2015","unstructured":"Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen JJ, Baron F, Unger R, Nagler A, Mohty M (2015) Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. J Clin Oncol 33(28):3144\u20133151. https:\/\/doi.org\/10.1200\/JCO.2014.59.1339","journal-title":"J Clin Oncol"},{"issue":"3","key":"6989_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1182\/bloodadvances.2018018549","volume":"3","author":"N Bejanyan","year":"2019","unstructured":"Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Ustun C, Warlick ED, Arora M, Wagner JE, Weisdorf DJ (2019) Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Adv 3(3):230\u2013236. https:\/\/doi.org\/10.1182\/bloodadvances.2018018549","journal-title":"Blood Adv"},{"issue":"1","key":"6989_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2019.09.006","volume":"26","author":"P Kongtim","year":"2020","unstructured":"Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO (2020) Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl 26(1):197\u2013203. https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.006","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"6989_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/bmt.2016.156","volume":"51","author":"M Pohlen","year":"2016","unstructured":"Pohlen M, Groth C, Sauer T, Gorlich D, Mesters R, Schliemann C, Lenz G, Muller-Tidow C, Buchner T, Berdel WE, Stelljes M (2016) Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (\u2a7e60 years). Bone Marrow Transpl 51(11):1441\u20131448. https:\/\/doi.org\/10.1038\/bmt.2016.156","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"6989_CR13","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.bbmt.2017.07.028","volume":"23","author":"R Potdar","year":"2017","unstructured":"Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R (2017) Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand? Biol Blood Marrow Transpl 23(11):1839\u20131846. https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.028","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"6989_CR14","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1182\/bloodadvances.2019032268","volume":"3","author":"R Shouval","year":"2019","unstructured":"Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, Yerushalmi R, Shimoni A, Nagler A (2019) External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv 3(12):1881\u20131890. https:\/\/doi.org\/10.1182\/bloodadvances.2019032268","journal-title":"Blood Adv"},{"issue":"12","key":"6989_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Lowenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"12","key":"6989_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41408-022-00764-9","volume":"12","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, Merz M, Vucinic V, Franke GN, Herling M, Platzbecker U, Schwind S (2022) Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J 12(12):170. https:\/\/doi.org\/10.1038\/s41408-022-00764-9","journal-title":"Blood Cancer J"},{"issue":"1","key":"6989_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-024-00487-6","volume":"13","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zheng X, Guo W, Xia Y, Zhang R, Zhai W, Chen X, Ma Q, Yang D, Wei J, Pang A, He Y, Feng S, Wang J, Han M, Jiang E (2024) Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol 13(1):16. https:\/\/doi.org\/10.1186\/s40164-024-00487-6","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"6989_CR18","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/s41375-024-02440-2","volume":"38","author":"W Chen","year":"2024","unstructured":"Chen W, Chen L, Cao Y, Jiang C, Luo Y, Ouyang G, Yu J, Tan Y, Lai X, Liu L (2024) Validation and refinement of the 2022 European LeukaemiaNet genetic risk classification of acute myeloid leukaemia patients receiving allogeneic haematopoietic cell transplantation. Leukemia 38(12):2712\u20132716","journal-title":"Leukemia"},{"issue":"27","key":"6989_CR19","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","volume":"25","author":"ML Sorror","year":"2007","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R (2007) Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25(27):4246\u20134254. https:\/\/doi.org\/10.1200\/JCO.2006.09.7865","journal-title":"J Clin Oncol"},{"issue":"17","key":"6989_CR20","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/jama.2011.1558","volume":"306","author":"ML Sorror","year":"2011","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindelov L, McSweeney PA, Hubel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R (2011) Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 306(17):1874\u20131883. https:\/\/doi.org\/10.1001\/jama.2011.1558","journal-title":"JAMA"},{"issue":"8","key":"6989_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","volume":"21","author":"ML Sorror","year":"2015","unstructured":"Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC (2015) Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transpl 21(8):1479\u20131487. https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.004","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"6989_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-024-02395-z","volume":"59","author":"M Janscak","year":"2024","unstructured":"Janscak M, Stelmes A, van den Berg J, Heim D, Halter J, Drexler B, Arranto C, Passweg J, Medinger M (2024) Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 59(11):1525\u20131533. https:\/\/doi.org\/10.1038\/s41409-024-02395-z","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"6989_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","volume":"18","author":"P Armand","year":"2012","unstructured":"Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ (2012) Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transpl 18(2):280\u2013288. https:\/\/doi.org\/10.1016\/j.bbmt.2011.07.024","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"6989_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl 15(3):367\u2013369. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"6989_CR25","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1038\/s41598-024-57016-y","volume":"14","author":"BBK Ip","year":"2024","unstructured":"Ip BBK, Wong ATC, Law JHY, Au CH, Ma SY, Chim JCS, Liang RHS, Leung AYH, Wan TSK, Ma ESK (2024) Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies. Sci Rep 14(1):6400. https:\/\/doi.org\/10.1038\/s41598-024-57016-y","journal-title":"Sci Rep"},{"issue":"7571","key":"6989_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"C Genomes Project","year":"2015","unstructured":"Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR (2015) A global reference for human genetic variation. Nature 526(7571):68\u201374. https:\/\/doi.org\/10.1038\/nature15393","journal-title":"Nature"},{"issue":"1","key":"6989_CR27","first-page":"8","volume":"38","author":"H Hung","year":"2010","unstructured":"Hung H, Chiang C-T (2010) Estimation methods for time-dependent AUC models with survival data. Can J Stat \/ La Revue Canadienne de Statistique 38(1):8\u201326","journal-title":"Can J Stat \/ La Revue Canadienne de Statistique"},{"key":"6989_CR28","doi-asserted-by":"publisher","unstructured":"Zhao D, Zarif M, Zhou Q, Capo-Chichi JM, Schuh A, Minden MD, Atenafu EG, Kumar R, Chang H (2023) TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation. Cancers (Basel) 15(12). https:\/\/doi.org\/10.3390\/cancers15123210","DOI":"10.3390\/cancers15123210"},{"issue":"3","key":"6989_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","volume":"8","author":"MT Nawas","year":"2024","unstructured":"Nawas MT, Kosuri S (2024) Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML. Blood Adv 8(3):553\u2013561. https:\/\/doi.org\/10.1182\/bloodadvances.2023010417","journal-title":"Blood Adv"},{"issue":"23","key":"6989_CR30","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023020855","volume":"142","author":"S Fleming","year":"2023","unstructured":"Fleming S, Tsai XC, Morris R, Hou HA, Wei AH (2023) TP53 status and impact on AML prognosis within the ELN 2022 risk classification. Blood 142(23):2029\u20132033. https:\/\/doi.org\/10.1182\/blood.2023020855","journal-title":"Blood"},{"issue":"6","key":"6989_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/ajh.27662","volume":"100","author":"RS Mehta","year":"2025","unstructured":"Mehta RS, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, Petitto GS, Lazaryan A, Singh A, Xue E, Dimitrova D, Hyder M, McCurdy S, Im A, Huber B, Aljawai YM, Kanakry J, Milano F, Kanakry CG (2025) Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. Am J Hematol 100(6):987\u2013997. https:\/\/doi.org\/10.1002\/ajh.27662","journal-title":"Am J Hematol"},{"key":"6989_CR32","doi-asserted-by":"publisher","unstructured":"Mehta RS, Aljawai YM, Al-Juhaishi T, Saultz J, Milano F, Kanakry JA, Kanakry CG, Lazaryan A (2025) Role of Donor Cytomegalovirus Serostatus in Cytomegalovirus-Seronegative Recipients of Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis. Transplant Cell Ther 31 (9):672 e671-672 e679. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.005","DOI":"10.1016\/j.jtct.2025.05.005"},{"issue":"3","key":"6989_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-020-0296-3","volume":"10","author":"AK Schmaelter","year":"2020","unstructured":"Schmaelter AK, Labopin M, Socie G, Itala-Remes M, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Ganser A, Beelen D, Labussiere-Wallet H, Passweg J, Savani BN, Schmid C, Nagler A, Mohty M (2020) Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J 10(3):26. https:\/\/doi.org\/10.1038\/s41408-020-0296-3","journal-title":"Blood Cancer J"},{"issue":"4","key":"6989_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/hon.3160","volume":"41","author":"C Nunez-Torron Stock","year":"2023","unstructured":"Nunez-Torron Stock C, Jimenez Chillon C, Martin Moro F, Marquet Palomanes J, Velazquez Kennedy K, Piris Villaespesa M, Roldan Santiago E, Rodriguez Martin E, Chinea Rodriguez A, Garcia Gutierrez V, Moreno Jimenez G, Lopez Jimenez J, Herrera Puente P (2023) Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry. Hematol Oncol 41(4):753\u2013761. https:\/\/doi.org\/10.1002\/hon.3160","journal-title":"Hematol Oncol"},{"issue":"8","key":"6989_CR35","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s00277-023-05324-0","volume":"102","author":"WJ Yu","year":"2023","unstructured":"Yu WJ, Sun YQ, Xu LP, Zhang XH, Liu KY, Huang XJ, Wang Y (2023) Comparison of outcomes for patients with acute myeloid leukemia undergoing haploidentical stem cell transplantation in first and second complete remission. Ann Hematol 102(8):2241\u20132250. https:\/\/doi.org\/10.1007\/s00277-023-05324-0","journal-title":"Ann Hematol"},{"issue":"15","key":"6989_CR36","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","volume":"6","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S (2022) Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv 6(15):4570\u20134580. https:\/\/doi.org\/10.1182\/bloodadvances.2022007168","journal-title":"Blood Adv"},{"issue":"7","key":"6989_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"24","key":"6989_CR38","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137\u20132145. https:\/\/doi.org\/10.1182\/blood.2020004856","journal-title":"Blood"},{"issue":"2","key":"6989_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","volume":"101","author":"O Pasvolsky","year":"2022","unstructured":"Pasvolsky O, Shimony S, Ram R, Shimoni A, Shargian L, Avni B, Wolach O, Shochat T, Yerushalmi R, Amit O, Raanani P, Yeshurun M (2022) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Ann Hematol 101(2):379\u2013387. https:\/\/doi.org\/10.1007\/s00277-021-04693-8","journal-title":"Ann Hematol"},{"key":"6989_CR40","doi-asserted-by":"publisher","unstructured":"Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA (2022) Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax\u2009+\u2009Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther 28 (10):694 e691-694 e699. https:\/\/doi.org\/10.1016\/j.jtct.2022.07.022","DOI":"10.1016\/j.jtct.2022.07.022"},{"issue":"14","key":"6989_CR41","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/bloodadvances.2022009632","volume":"7","author":"NJ Short","year":"2023","unstructured":"Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U (2023) Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv 7(14):3573\u20133581. https:\/\/doi.org\/10.1182\/bloodadvances.2022009632","journal-title":"Blood Adv"},{"issue":"9","key":"6989_CR42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D (2020) Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood 135(9):680\u2013688. https:\/\/doi.org\/10.1182\/blood.2019002959","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06989-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06989-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06989-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:39:32Z","timestamp":1781645972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06989-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6989"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06989-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the University of Hong Kong (UW 24\u2013621) and Ethics Committee of Clinical Trial of the First Affiliated Hospital of Zhejiang University (IIT20200086C-R1) and was conducted in accordance to the Declaration of Helsinki. All patients gave informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}